Stefan Gross has served as biochemistry lead and launch team member in multiple startup ventures and is currently Director, Enzymology at Agios Pharmaceuticals. As the second employee, he played a key role in building Agios from a paper concept to a multibillion dollar public and commercial company. Stefan’s work at the intersections of rare genetic diseases, cancer metabolism, and enzymology led to the discovery of the first oncometabolite, 2HG, produced by the first described cancer-associated gain-of-function mutations in isocitrate dehydrogenase. His team produced two first-in-class inhibitors of mutant IDH1 and IDH2, Ivosidenib and Enasidenib, each of which achieved POC in Phase I trials. Prior to Agios, Stefan held positions of increasing responsibility as a key early hire at at Ore Pharmaceuticals, Altus Pharmaceuticals, and Archemix Corporation after academic training at the Sackler School of Graduate Biomedical Sciences, Tufts University. His professional enthusiasms include enzyme kinetics, small molecule drug discovery, and leading passionate teams to build great companies that help patients.